Cat. No. | Product name | CAS No. |
DCC2950 |
Kr-12-a4
Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity |
|
DCC2951 |
Kr-25210
Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus |
|
DCC2952 |
Kr-31762
Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury |
|
DCC2953 |
Kras(g12c)-in-1
Novel irreversible inhibitor of KRAS(G12C) |
|
DCC2954 |
Kras4b-in-d14
Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells |
924249-06-9 |
DCC2955 |
Kras4b-pdeδ Stabilizer C19
Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling |
1049727-35-6 |
DCC2956 |
Krc-108
Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met |
1146944-35-5 |
DCC2957 |
Krc-327
Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. |
1350612-75-7 |
DCC2958 |
Krm-ii-08
Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c |
|
DCC2959 |
Krn4884
Potassium channel opener |
152802-84-1 |
DCC2960 |
Krn-8602 Hydrochloride
Topo II inhibitor, exhibiting cytotoxic effects against tumour cells |
131722-57-1 |
DCC2961 |
Krp-109
Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes |
1275996-50-3 |
DCC2962 |
Krp-199
Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo |
221164-28-9 |
DCC2963 |
Krp-204
Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity |
220475-76-3 |
DCC2964 |
Ks-133
Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders |
|
DCC2965 |
Ksc-392-150
Novel inhibitor of the permeability transition pore (PTP) |
|
DCC2966 |
kscm-1
Selective ligand of the sigma-1 receptor |
1415247-17-4 |
DCC2967 |
Kscm-11
Ligand of the sigma receptor |
1415247-16-3 |
DCC2968 |
kscm-5
Ligand of the sigma receptor |
1415247-18-5 |
DCC2969 |
Ksk120
Novel inhibitor of transcriptional activity in Chlamydia trachomatis |
1638100-63-6 |
DCC2970 |
Ksl-128114
Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma |
|
DCC2971 |
Kspa-1
Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP |
264207-32-1 |